Söner Serdar, Güzel Tuncay, Aktan Adem, Kılıç Raif, Söner Hülya Tosun, Demir Muhammed, Kaya Ahmet Ferhat, Taştan Ercan, Okşul Metin, Cömert Adnan Duha, Arslan Gamze Yeter, Baysal Erkan, Ertaş Faruk
Department of Cardiology, Gazi Yaşargil Training and Research Hospital, Health Science University, Diyarbakır, 21070, Turkey.
Department of Cardiology, Mardin Artuklu University, Mardin, Turkey.
BMC Cardiovasc Disord. 2025 Jul 19;25(1):528. doi: 10.1186/s12872-025-04993-1.
The relationship between hemoglobin, albumin, lymphocyte, platelet (HALP) score, and various cancers and cardiovascular diseases has been tested previously. However, the relationship between HALP score and non-valvular atrial fibrillation (NVAF) has not been adequately tested. Therefore, our study aimed to investigate the relationship between HALP score and mortality in patients with NVAF.
This study included 2,592 NVAF patients from 35 centers in Turkey. Patients were divided into two groups: those with HALP scores ≤ 58.96 (low HALP score group, 1,296 patients) and > 58.96 (high HALP score group, 1,296 patients). The primary outcome measured was all-cause mortality.
The mean HALP score was 66 ± 33. Patients in the low HALP score group had higher 1- and 5-year all-cause mortality rates (1-year: 12.9% vs. 5.4%, p < 0.001; 5-year: 38.5% vs. 20.2%, p < 0.001). Cox regression analysis identified the HALP score as an independent predictor of mortality (1-year: HR = 0.987, 95% CI = 0.981-0.992, p < 0.001; 5-year: HR = 0.990, 95% CI = 0.987-0.993, p < 0.001). ROC analysis determined a HALP score 52.3 predicted 1-year mortality with 62.9% sensitivity and 62% specificity (AUC = 0.680); a score of 55 predicted 5-year mortality with 60.3% sensitivity and 62.2% specificity (AUC = 0.657). Kaplan-Meier analysis revealed increasing mortality over time in the low HALP score group (log-rank tests, 1-year = 44.86, p < 0.001; 5-year = 108.54, p < 0.001).
The HALP score is a simple, accessible measure, and our findings suggest that lower HALP scores are associated with increased 1-year and 5-year mortality in NVAF patients. This provides a reference for clinicians assessing risk in this vulnerable population.
血红蛋白、白蛋白、淋巴细胞、血小板（HALP）评分与各种癌症和心血管疾病之间的关系此前已得到验证。然而，HALP评分与非瓣膜性心房颤动（NVAF）之间的关系尚未得到充分验证。因此，我们的研究旨在探讨HALP评分与NVAF患者死亡率之间的关系。
本研究纳入了来自土耳其35个中心的2592例NVAF患者。患者分为两组：HALP评分≤58.96的患者（低HALP评分组，1296例患者）和>58.96的患者（高HALP评分组，1296例患者）。测量的主要结局是全因死亡率。
HALP评分的平均值为66±33。低HALP评分组患者的1年和5年全因死亡率较高（1年：12.9%对5.4%，p<0.001；5年：38.5%对20.2%，p<0.001）。Cox回归分析确定HALP评分为死亡率的独立预测因素（1年：HR=0.987，95%CI=0.981-0.992，p<0.001；5年：HR=0.990，95%CI=0.987-0.993，p<0.001）。ROC分析确定HALP评分52.3预测1年死亡率的敏感度为62.9%，特异度为62%（AUC=0.680）；评分55预测5年死亡率的敏感度为60.3%，特异度为62.2%（AUC=0.657）。Kaplan-Meier分析显示低HALP评分组的死亡率随时间增加（对数秩检验，1年=44.86，p<0.001；5年=108.54，p<0.001）。
HALP评分是一种简单、可获取的测量方法，我们的研究结果表明，较低的HALP评分与NVAF患者1年和5年死亡率增加相关。这为临床医生评估这一脆弱人群的风险提供了参考。
